Candriam S.C.A. Igm Biosciences, Inc. Transaction History

Candriam S.C.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$8.86 - $14.0 $113,328 - $179,074	-12,791 Reduced 6.81%	175,008 $1.62 Million
Q1 2023 May 12, 2023	BUY	$13.74 - $25.76 $395,904 - $742,248	28,814 Added 18.12%	187,799 $2.58 Million
Q4 2022 Feb 13, 2023	BUY	$15.45 - $26.02 $1.7 Million - $2.87 Million	110,225 Added 226.06%	158,985 $2.7 Million
Q3 2022 Nov 10, 2022	BUY	$15.42 - $27.01 $751,879 - $1.32 Million	48,760 New	48,760 $1.11 Million
Q3 2021 Nov 09, 2021	SELL	$65.76 - $90.65 $8.02 Million - $11.1 Million	-122,029 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$57.98 - $96.6 $761,683 - $1.27 Million	13,137 Added 12.06%	122,029 $10.2 Million
Q4 2020 Jan 22, 2021	SELL	$47.41 - $115.03 $1.01 Million - $2.46 Million	-21,395 Reduced 16.42%	108,892 $9.61 Million
Q3 2020 Oct 19, 2020	SELL	$43.0 - $84.01 $261,483 - $510,864	-6,081 Reduced 4.46%	130,287 $9.62 Million
Q2 2020 Jul 23, 2020	BUY	$51.3 - $75.21 $7 Million - $10.3 Million	136,360 Added 1704500.0%	136,368 $9.96 Million
Q1 2020 May 26, 2020	BUY	$31.51 - $73.75 $252 - $590	8 New	8 $0

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.